|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goldstraw P, Ball D, Jett JR, Le Chevalier
T, Lim E, Nicholson AG and Shepherd FA: Non-small-cell lung cancer.
Lancet. 378:1727–1740. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Choudhary C, Kumar C, Gnad F, Nielsen ML,
Rehman M, Walther TC, Olsen JV and Mann M: Lysine acetylation
targets protein complexes and co-regulates major cellular
functions. Science. 325:834–840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim SC, Sprung R, Chen Y, Xu Y, Ball H,
Pei J, Cheng T, Kho Y, Xiao H, Xiao L, et al: Substrate and
functional diversity of lysine acetylation revealed by a proteomics
survey. Mol Cell. 23:607–618. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guan KL and Xiong Y: Regulation of
intermediary metabolism by protein acetylation. Trends Biochem Sci.
36:108–116. 2011. View Article : Google Scholar :
|
|
8
|
Ahn BH, Kim HS, Song S, Lee IH, Liu J,
Vassilopoulos A, Deng CX and Finkel T: A role for the mitochondrial
deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad
Sci USA. 105:14447–14452. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jing E, Emanuelli B, Hirschey MD, Boucher
J, Lee KY, Lombard D, Verdin EM and Kahn CR: Sirtuin-3 (Sirt3)
regulates skeletal muscle metabolism and insulin signaling via
altered mitochondrial oxidation and reactive oxygen species
production. Proc Natl Acad Sci USA. 108:14608–14613. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sundaresan NR, Samant SA, Pillai VB,
Rajamohan SB and Gupta MP: SIRT3 is a stress-responsive deacetylase
in cardiomyocytes that protects cells from stress-mediated cell
death by deacetylation of Ku70. Mol Cell Biol. 28:6384–6401. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar S and Lombard DB: Mitochondrial
sirtuins and their relationships with metabolic disease and cancer.
Antioxid Redox Signal. 22:1060–1077. 2015. View Article : Google Scholar :
|
|
12
|
Haigis MC, Deng CX, Finley LWS, Kim HS and
Gius D: SIRT3 is a mitochondrial tumor suppressor: A scientific
tale that connects aberrant cellular ROS, the Warburg effect, and
carcinogenesis. Cancer Res. 72:2468–2472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Finley LWS and Haigis MC: Metabolic
regulation by SIRT3: Implications for tumorigenesis. Trends Mol
Med. 18:516–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alhazzazi TY, Kamarajan P, Verdin E and
Kapila YL: Sirtuin-3 (SIRT3) and the hallmarks of cancer. Genes
Cancer. 4:164–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen Y, Fu LL, Wen X, Wang XY, Liu J,
Cheng Y and Huang J: Sirtuin-3 (SIRT3), a therapeutic target with
oncogenic and tumor-suppressive function in cancer. Cell Death Dis.
5:e10472014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiong Y, Wang M, Zhao J, Han Y and Jia L:
Sirtuin 3: A Janus face in cancer (Review). Int J Oncol.
49:2227–2235. 2016.PubMed/NCBI
|
|
17
|
Budwit-Novotny DA, McCarty KS, Cox EB,
Soper JT, Mutch DG, Creasman WT, Flowers JL and McCarty KS Jr:
Immunohistochemical analyses of estrogen receptor in endometrial
adenocarcinoma using a monoclonal antibody. Cancer Res.
46:5419–5425. 1986.PubMed/NCBI
|
|
18
|
Shin SJ, Roh J, Cha HJ, Choi YD, Kim JM,
Min SK, Kim JE, Eom DW, Lee H, Kim HJ, et al: TCL1 expression
predicts overall survival in patients with mantle cell lymphoma.
Eur J Haematol. 95:583–594. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
DeLong ER, DeLong DM and Clarke-Pearson
DL: Comparing the areas under two or more correlated receiver
operating characteristic curves: A nonparametric approach.
Biometrics. 44:837–845. 1988. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cai MY, Zhang B, He WP, Yang GF, Rao HL,
Rao ZY, Wu QL, Guan XY, Kung HF, Zeng YX, et al: Decreased
expression of Pinx1 protein is correlated with tumor development
and is a new independent poor prognostic factor in ovarian
carcinoma. Cancer Sci. 101:1543–1549. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zlobec I, Steele R, Terracciano L, Jass JR
and Lugli A: Selecting immunohistochemical cut-off scores for novel
biomarkers of progression and survival in colorectal cancer. J Clin
Pathol. 60:1112–1116. 2007. View Article : Google Scholar
|
|
22
|
Bell EL, Emerling BM, Ricoult SJH and
Guarente L: SirT3 suppresses hypoxia inducible factor 1α and tumor
growth by inhibiting mitochondrial ROS production. Oncogene.
30:2986–2996. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wei L, Zhou Y, Qiao C, Ni T, Li Z, You Q,
Guo Q and Lu N: Oroxylin A inhibits glycolysis-dependent
proliferation of human breast cancer via promoting SIRT3-mediated
SOD2 transcription and HIF1α destabilization. Cell Death Dis.
6:e17142015. View Article : Google Scholar
|
|
24
|
Zhao K, Zhou Y, Qiao C, Ni T, Li Z, Wang
X, Guo Q, Lu N and Wei L: Oroxylin A promotes PTEN-mediated
negative regulation of MDM2 transcription via SIRT3-mediated
deacetylation to stabilize p53 and inhibit glycolysis in wt-p53
cancer cells. J Hematol Oncol. 8:412015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xiao K, Jiang J, Wang W, Cao S, Zhu L,
Zeng H, Ouyang R, Zhou R and Chen P: Sirt3 is a tumor suppressor in
lung adenocarcinoma cells. Oncol Rep. 30:1323–1328. 2013.PubMed/NCBI
|
|
26
|
Zhao Y, Yang H, Wang X, Zhang R, Wang C
and Guo Z: Sirtuin-3 (SIRT3) expression is associated with overall
survival in esophageal cancer. Ann Diagn Pathol. 17:483–485. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alhazzazi TY, Kamarajan P, Joo N, Huang
JY, Verdin E, D'Silva NJ and Kapila YL: Sirtuin-3 (SIRT3), a novel
potential therapeutic target for oral cancer. Cancer.
117:1670–1678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li H, Feng Z, Wu W, Li J, Zhang J and Xia
T: SIRT3 regulates cell proliferation and apoptosis related to
energy metabolism in non-small cell lung cancer cells through
deacetylation of NMNAT2. Int J Oncol. 43:1420–1430. 2013.PubMed/NCBI
|
|
29
|
Zhang YY and Zhou LM: Sirt3 inhibits
hepatocellular carcinoma cell growth through reducing Mdm2-mediated
p53 degradation. Biochem Biophys Res Commun. 423:26–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Quan Y, Wang N, Chen Q, Xu J, Cheng W, Di
M, Xia W and Gao WQ: SIRT3 inhibits prostate cancer by
destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt
pathway. Oncotarget. 6:26494–26507. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pillai VB, Sundaresan NR and Gupta MP:
Regulation of Akt signaling by sirtuins: Its implication in cardiac
hypertrophy and aging. Circ Res. 114:368–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chan CH, Jo U, Kohrman A, Rezaeian AH,
Chou PC, Logothetis C and Lin HK: Posttranslational regulation of
Akt in human cancer. Cell Biosci. 4:592014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Risso G, Blaustein M, Pozzi B, Mammi P and
Srebrow A: Akt/PKB: One kinase, many modifications. Biochem J.
468:203–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bauer TM, Patel MR and Infante JR:
Targeting PI3 kinase in cancer. Pharmacol Ther. 146:53–60. 2015.
View Article : Google Scholar
|
|
36
|
Testa JR and Bellacosa A: AKT plays a
central role in tumorigenesis. Proc Natl Acad Sci USA.
98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sundaresan NR, Pillai VB, Wolfgeher D,
Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta
M and Gupta MP: The deacetylase SIRT1 promotes membrane
localization and activation of Akt and PDK1 during tumorigenesis
and cardiac hypertrophy. Sci Signal. 4:ra462011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
George J, Nihal M, Singh CK, Zhong W, Liu
X and Ahmad N: Pro-proliferative function of mitochondrial sirtuin
deacetylase SIRT3 in human melanoma. J Invest Dermatol.
136:809–818. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Choi J, Koh E, Lee YS, Lee HW, Kang HG,
Yoon YE, Han WK, Choi KH and Kim KS: Mitochondrial Sirt3 supports
cell proliferation by regulating glutamine-dependent oxidation in
renal cell carcinoma. Biochem Biophys Res Commun. 474:547–553.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weinstein IB: Cancer. Addiction to
oncogenes - the Achilles heal of cancer. Science. 297:63–64. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fisher GH, Wellen SL, Klimstra D,
Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A and
Varmus HE: Induction and apoptotic regression of lung
adenocarcinomas by regulation of a K-Ras transgene in the presence
and absence of tumor suppressor genes. Genes Dev. 15:3249–3262.
2001. View Article : Google Scholar : PubMed/NCBI
|
